SNW2 Stock Chart & Stats
€38.80
€0.20(0.53%)
At close: 4:00 PM EDT
€38.80
€0.20(0.53%)
Day’s Range― - ―
52-Week Range€34.60 - €45.00
Previous CloseN/A
Volume0.00
Average Volume (3M)170.00
Market Cap
€85.79B
Enterprise Value€122.96B
Total Cash (Recent Filing)€6.35B
Total Debt (Recent Filing)€23.58B
Price to Earnings (P/E)21.9
Beta0.49
Next Earnings
Oct 30, 2026EPS Estimate
1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding2,415,546,900
10 Day Avg. Volume512
30 Day Avg. Volume170
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.15
P/FCF Ratio9.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.06Price Target Upside36.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.36
Revenue Forecast (FY)€50.24B
Bulls Say, Bears Say
Bulls Say
Steady Revenue ExpansionSanofi has delivered several years of revenue expansion, including stronger growth in 2025. Continued top-line progress indicates broad demand across its medicines and vaccines portfolio, supporting investment in research, launches, and commercial capabilities over the next several quarters.
Conservative Balance SheetA substantial equity base and moderate leverage give Sanofi financial flexibility to fund research, business development, and operations. This capital structure should improve resilience through product-cycle volatility while limiting the burden of debt service on future cash generation.
Broader Oncology FranchiseThe Sarclisa delivery approval expands treatment flexibility while reducing administration time and infusion-related reactions. By improving patient convenience and clinic efficiency, the innovation can strengthen Sarclisa’s competitive position and support durable growth in multiple myeloma.
Bears Say
Operating Margin PressureFalling EBIT while revenue increased shows that sales growth is not currently translating fully into operating profit. If higher operating costs or mix pressure persist, margin compression could limit earnings growth and reduce the benefit of Sanofi’s expanding commercial base.
Volatile Free Cash FlowSanofi generates positive cash overall, but substantial year-to-year variability makes internally funded growth and shareholder distributions less predictable. Weaker earnings-to-cash conversion in 2024 also suggests that reported profitability may not consistently convert into deployable liquidity.
Balance-sheet Trend WeakenedAlthough leverage remains moderate, rising debt alongside lower equity represents a deterioration in balance-sheet direction. If this trend continues, it could gradually reduce financial flexibility and leave fewer resources available for acquisitions, research investment, or resilience during weaker periods.
Sanofi News
SNW2 FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €34.60 and its highest was €45.00 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €85.79B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 30, 2026 which is in 18 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 30, 2026. The company reported €1.072 earnings per share for the quarter, beating the consensus estimate of €0.97 by €0.102.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi does not currently pay dividends.
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.4.
How many shares outstanding does Sanofi have?
Sanofi has 2,415,546,900 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €1.072 in its last earnings report, beating expectations of €0.97. Following the earnings report the stock price went down -9.548%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in DE:SNW2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanofi Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€53.06 (36.76% Upside)
€53.06 (36.76% Upside)
Blogger Sentiment
Bullish
DE:SNW2 Sentiment 89%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.65%
12-Months-Change
Fundamentals
Return on Equity
5.52%
Trailing 12-Months
Asset Growth
0.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
SNW2 Company Deck
SNW2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.View all DE:SNW2 earnings summariesSNW2 Stock 12 Month Forecast
Average Price Target
€53.06
▲(36.76% Upside)